Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and ChromaDex Corporation (NASDAQ:CDXC) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Alexion Pharmaceuticals Inc. and ChromaDex Corporation.

Profitability

Table 2 has Alexion Pharmaceuticals Inc. and ChromaDex Corporation’s net margins, return on assets and return on equity.

Volatility and Risk

Alexion Pharmaceuticals Inc. has a beta of 1.53 and its 53.00% more volatile than S&P 500. Competitively, ChromaDex Corporation’s beta is 1.06 which is 6.00% more volatile than S&P 500.

Liquidity

The Current Ratio of Alexion Pharmaceuticals Inc. is 3.9 while its Quick Ratio stands at 3.4. The Current Ratio of rival ChromaDex Corporation is 2.5 and its Quick Ratio is has 2. Alexion Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than ChromaDex Corporation.

Analyst Ratings

Alexion Pharmaceuticals Inc. and ChromaDex Corporation Ratings and Recommendations are available on the next table.

Alexion Pharmaceuticals Inc.’s upside potential currently stands at 21.44% and an $162.83 consensus price target.

Institutional and Insider Ownership

The shares of both Alexion Pharmaceuticals Inc. and ChromaDex Corporation are owned by institutional investors at 96.9% and 17.6% respectively. Insiders held roughly 0.2% of Alexion Pharmaceuticals Inc.’s shares. On the other hand, insiders held about 3.1% of ChromaDex Corporation’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Alexion Pharmaceuticals Inc.’s stock price has smaller growth than ChromaDex Corporation.

Summary

Alexion Pharmaceuticals Inc. beats ChromaDex Corporation on 8 of the 9 factors.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.